$80.21
1.47% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Insmed Incorporated Stock price

$79.05
+1.42 1.83% 1M
+1.94 2.52% 6M
+10.01 14.50% YTD
+49.82 170.44% 1Y
+55.15 230.75% 3Y
+54.85 226.65% 5Y
+60.51 326.38% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.95 1.22%
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Key metrics

Market capitalization $14.31b
Enterprise Value $14.19b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 39.01
P/S ratio (TTM) P/S ratio 39.34
P/B ratio (TTM) P/B ratio 49.69
Revenue growth (TTM) Revenue growth 19.17%
Revenue (TTM) Revenue $363.71m
EBIT (operating result TTM) EBIT $-786.57m
Free Cash Flow (TTM) Free Cash Flow $-705.81m
Cash position $1.43b
EPS (TTM) EPS $-5.59
P/E forward negative
P/S forward 30.35
EV/Sales forward 30.10
Short interest 8.09%
Show more

Is Insmed Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Insmed Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Insmed Incorporated forecast:

18x Buy
100%

Analyst Opinions

18 Analysts have issued a Insmed Incorporated forecast:

Buy
100%

Financial data from Insmed Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
364 364
19% 19%
100%
- Direct Costs 91 91
29% 29%
25%
273 273
16% 16%
75%
- Selling and Administrative Expenses 450 450
38% 38%
124%
- Research and Development Expense 598 598
5% 5%
165%
-776 -776
17% 17%
-213%
- Depreciation and Amortization 11 11
42% 42%
3%
EBIT (Operating Income) EBIT -787 -787
16% 16%
-216%
Net Profit -914 -914
22% 22%
-251%

In millions USD.

Don't miss a Thing! We will send you all news about Insmed Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insmed Incorporated Stock News

Neutral
PRNewsWire
4 days ago
—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug ...
Neutral
Seeking Alpha
8 days ago
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
8 days ago
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— —NDA for Brensocatib in...
More Insmed Incorporated News

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Will Lewis
Employees 1,271
Founded 1988
Website www.insmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today